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Abstract The voltage dependent anion-channel, VDAC, is
the major constitutive protein of the outer membrane of
mitochondria. Functionally, VDAC is involved in the ex-
change of small metabolites over the mitochondrial outer
membrane and supports enzymes of the cytoplasm with
energy precursors i.e. ATP. Moreover, the channel alone or in
complex with proteins of the inner mitochondrial membrane
or the intermembrane space provides a basis for docking of
cytosolic proteins which can regulate outer membrane
permeability in several ways. Structurally, this channel has a
bacterial origin by evolution and partly resembles bacterial
porin functions. However, the structure seems more complex
as a variety of interactions on both channel sides can occur.
Therefore, our work described is aiming to determine the
structure of VDAC at atomic resolution and together with
functional data to understand better how this channel can carry
out such a variety of differing functions.
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Introduction
The outer membrane of mitochondria harbors four integral
membrane proteins or membrane protein complexes,
respectively. This finding is in strong contrast to a typically
large number of proteins predicted to exist in the outer
membrane of most Gram-negative bacteria, which are
related to mitochondria through the endosymbiotic theory.
Even with this small subset of proteins it enables the full
communication between mitochondria and the cellular
environment. Interestingly, three of these mitochondrial
outer membrane complexes (the general import pore TOM,
the SAM and MDM10 complexes) allow for the entire
translocation and insertion of all newly synthesized proteins
destined to the mitochondrial organelle (Bolender et al.
2008). The fourth protein family of voltage dependent
anion-channels (VDACs) was initially described as being
reminiscent of bacterial porins and to be mainly responsible
for the exchange of chemical energy from the cytosol to the
mitochondrion and vice versa (Bowen et al. 1985; Guo et
al. 1995). This subset of channel proteins typically occurs
with a high sequence homology between unicellular and
higher eukaryotes and a sequence identity of >80%
between up to three isoforms which are observed in mam-
mals. Among all mitochondria studied by semi-quantitative
methods this class of proteins is the most abundant specimen
found in the MOM (Mannella 1998a, b). In human three
different isoforms HVDAC1–HVDAC3 with high sequence
analogy (>80%) exist according to the genome (Young et
al. 2007). However, these isoforms are not only regulated in
their relative abundance in differing cell types but they can
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also be found in phosphorylated states at certain stages of
the cell cycle and specific functions can thereby be
stimulated accordingly (Schwertz et al. 2007).
VDAC from Saccharomyces cerevisiae and Neurospora
crassa were the first VDAC proteins isolated and studied
by various biophysical techniques. However, first structural
snapshots at medium resolution were derived from
HVDAC1 and VDAC from N. crassa by electron micros-
copy of 2D crystals (Mannella 1998a, b; Dolder et al.
1999). Together with single channel conductance methods
used to characterize this protein channel the passive
diffusion of small metabolites in mitochondria was tested
and the protein and was treated in function similarly to the
related bacterial porins. However, several years ago this
functional view turned out to be insufficient since in fungi a
number of interactions between VDAC and e.g. the ANT of
the inner membrane are said to be missing in the bacterial
precursors (Komarov et al. 2005). Among these functions
the involvement in coupling mitochondria with energy
maintenance is the most prominent function described so
far (Pastorino and Hoek 2003). For the three isoforms
appearing in mammals a variety of interactions between
these proteins have been described on both sides of the
membrane placing VDAC proteins in the center of the
mitochondrial communication (Brdiczka et al. 1998).
While interactions with the inter membrane space of
mitochondria are typically related to energy metabolism,
the interplay with the cytosol appears to be even more
complex. VDAC is described to be involved in interactions
with a growing number of proteins, most of which are
involved in the mitochondrial phase of apoptosis. Initially, a
supramolecular pore channel (also termed the permeability
transition pore, PTP) including VDAC and ANT from the
inner membrane spanning both membranes was proposed to
be regulated by factors which may lead to the breakdown of
the inner membrane potential (Bernardi and Forte 2007;
Grimm and Brdiczka 2007). However, another way of
describing the active functioning of VDAC in related
apoptotic pathways emerges and it appears that more and
more additional functions may be addressed. Here,
HVDAC1 was described to anchor proteins e.g. tBid or
Bcl-xl to the outer membrane and to induce mitochondrial
apoptosis by a controlled multi-step process (Rostovtseva et
al. 2004; Malia and Wagner 2007). By contrast isoform II
has been described to directly bind the pro-apoptotic
member Bak and to potentially facilitate insertion and
association of Bak into pores which can release mitochon-
drial cyt c that will induce downstream apoptosis (Cheng et
al. 2003). Recently, the attachment of the lipid synthesis
protein STAR to VDAC during the life cycle of a
eukaryotic cell was described (Bose et al. 2008). Other
reports depict VDAC as part of a tRNA uptake system in
plant cells (Salinas et al. 2006).
In recent years several reports described the mitochon-
drial VDAC as a potential target for pharmaceutical
research. Several drugs were described that potentially bind
to VDAC as their target molecule in vivo. As a basis for a
more thorough understanding of the functional role of
VDAC alone and VDAC-complexes in biology and to
allow further target screening of VDAC using the most
prominent isoform I from human we set out to structurally
characterize the protein by biophysical techniques including
electron microscopy and X-ray crystallography.
Characterization of recombinant HVDAC1
In our lab the human isoforms I and II were over-expressed
in Escherichia coli as insoluble inclusion bodies and a
refolding procedure was established that allowed producing
quantities of around 100 mg of both isoforms within
1 week. The correct fold of the protein was initially tested
using secondary structure assignment methods like FTIR-
and CD-spectroscopy (see Fig. 1a,b). Both methods clearly
indicated proper folding of the target protein yielding an
approximate overall content of 46% β-sheet structure and a
α-helical contribution of 10%. These values are in good
agreement with values determined for VDAC proteins from
fungi and a more closely related VDAC from plants (Shao
et al. 1996; Koppel et al. 1998; Desai et al. 2006).
Another way of testing the correct fold of an outer
membrane protein is to determine a possible gel shift in
SDS-gels under non-denaturing conditions. These experi-
ments have proven to be quite successful in the case of the
bacterial outer membrane proteins (Sukumaran et al. 2006;
Minetti et al. 1997). However, for the eukaryotic porin and
homologs of the mitochondrial outer membrane this
method failed probably because temperature transition of
the β-barrel to the unfolded state already occurred at around
40 degrees (for HVDAC1: data obtained from CD-melting
curves, data not shown). Nevertheless, cross-linking experi-
ments of the recombinantly produced and refolded protein
yielded both monomeric and a significant amount of dimeric
species in SDS-gels. This may be taken as another indicator
of proper folding since apparently oligomerization of the
protein occurred (see Fig. 1c).
Complexes of HVDAC1 with the pro-apoptotic protein
cBid
Other ways to test for the correct fold of a protein are
looking for enzymatic activity or the ability to interact with
binding partners described as in the literature (Rostovtseva
et al. 2004). An interaction between HVDAC1 and cBid is
described in the literature based on electrophysiological
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measurements and this seems at present the most reliable
system to study. However, a direct interaction of both
proteins has never been proven physically. In order to be
able to study such complexes by X-ray crystallographic
techniques we have purified both protein compounds to
check the possible interaction between HVDAC1 and cBid
by cross-linking using glutar aldehyde and can demonstrate
an interaction on SDS-PAGE. A 1:1 complex of VDAC and
cBid is clearly visible as well as a smaller fraction of the
hetero-trimeric complex (VDAC:cBid—2:1 ratio, Fig. 1c).
A potential influence of cBid on the monomer–dimer
equilibrium might be envisaged.
Electron microscopy of HVDAC1
Electron microscopy of membrane proteins embedded
into a lipid bilayer often results in data to medium or
close-to-atomic resolution. In order to achieve such a
resolution we transferred VDAC into lipid bilayer and
determined electron micrographs of such vesicles.
Although the order of the protein was good and data
to a resolution of approx. 8 Å could be obtained for
laterally arranged protein aggregates, the conclusion to
be drawn from these experiments is rather limited since
only multi-layered crystals could be obtained during this
analysis. In order to characterize the molecular surface
of these 2D-crystal arrays and to obtain a complemen-
tary view the crystals were shadowed from a certain
angle of incidence with a thin layer of heavy atoms and
those images allowed the identification of the shape of a
single protein specimen. From these images it seems
likely that the protein forms a dimer which is consistent
with results from cross-linking and X-ray crystallogra-
phy. The pore diameter was estimated to be between 4
and 5 nm depending on which of the pore sides was
chosen (Fig. 2).
Fig. 1 Secondary structure assignment of HVDAC1 and interaction
studies with human cBid. a CD-spectra of HVDAC1 determined in
1% of β-octyl-glucoside as the detergent. The spectrum shows a β-
structure contribution of approx. 45% plus an overestimated fraction
of about 22% α-helix. b FTIR-spectrum of human VDAC1 in 0.8%
C8E4 as the detergent. The β-sheet structure was calculated to be
48%, while the α-helical contribution is approx. 7%. c Cross-link
experiments with human VDAC1, alone, isolated human cBid, and a
1:1 mixture of both proteins in the presence of glutar aldehyde. A
significant portion of HVDAC1 (VDAC + GA) was cross-linked to
yield a strong dimer band plus additional weak band of trimers.
Interestingly, the cross-linked monomer runs at a lower molecular
weight of less than 30 kD probably due to cross-link reactions
between adjacent strands of the barrel or a helix–barrel crosslink,
respectively. Cross-linking between the two fragments of cBid
(cBID) after caspase treatment does not occur between the two
domains. However, conformational changes occur in cBid upon
addition of β-octyl-glucoside and glutar aldehyde to yield a higher
molecular weight specimen (cBID+GA+OG). Cross-linking of
VDAC and cBid (VDAC+cBID+GA) yielded a distribution of
dominant 1:1 complexes and a small amount of 1:2 and 2:2 specimen.
A small shift of the equilibrium towards the monomeric VDAC might
be envisaged (VDAC+cBID+GA)

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The structure of HVDAC1 at higher resolution
To obtain a picture of the channel at higher resolution we
used our protein preparation method for the crystallization
and screening of 3D-crystals diffracting to atomic resolu-
tion. Testing of different detergents lead to initial crystals
which often diffracted to not better than 20 Å resolution.
Using Cymal-5 as detergent this resolution could be
dramatically improved leading to crystals diffracting to
3.5 Å resolution. Although this resolution in principle
should allow a protein model to be built within a good
quality electron density map, experimental phasing of the
crystals was so far hampered by several factors including
the low number of natively present methionines for SeMet-
phasing and the relatively poor diffraction limit. Using
initial phases based on SeMet-doped crystals and multiple
anomalous dispersion (MAD) techniques together with Pt-
based multiple isomorphous replacement an electron den-
sity with phases up to 6 Å was derived that showed the
barrel wall and a number of β-strands together with the N-
terminal α-helix in a clear view. Moreover, the dimeric
origin of the protein complex by rather small protein–
protein interfaces can be seen easily. Details of the structure
are currently not available since phase information to higher
resolution is still missing (Fig. 3).
Biological implications and outlook
VDACs in unicellular eukaryotes i.e. S. cerevisiae differ in
the complexity of interactions they are involved in as part
of the entire cell. Although an apoptotic pathway in yeast
has been delineated in the literature, an involvement of
VDAC isoforms in this pathway could not be addressed
(Mazzoni and Falcone 2008). By contrast in multi-cellular
organisms and with the evolution of sophisticated apoptotic
mechanisms the mitochondrial control over the fate of a
certain cell became more and more evident. Complexes of
VDAC with apoptotic factors i.e. cBid or Bak are of
biological importance as these factors among others can
stimulate a decision about life or death of a certain cell. To
control this process more tightly medical treatment may
help in certain diseases where cellular life is controlled in a
too strict and abnormal way. Such phenomena are found
among neuron-degenerative disorders and a pharmacolog-
ical intervention into the interplay of VDAC and apoptotic
Fig. 2 Electron micrographs of
human VDAC1. Diffraction
pattern computed based on 2D-
crystals of VDAC embedded in
vitreous ice and freeze dried and
shadowed (c–e), respectively. a
Diffraction spots are visible up
to 8.2 Å resolution (see white
circle) with a scale bar of
0.6 nm−1. b The vectors of the
reciprocal space are marked
with a and b. The low density
lumens are surrounded by rims
of higher density (see arrows)
and yield an approximate diam-
eter of three nanometers. c
Three dimensional perspective
view of freeze dried and shad-
owed crystals calculated from
six single images with different
azimuths and an elevation angle
of 65° (scale bar 5 nm). Protru-
sions are marked with asterisks.
d Top view of the reconstructed
surface (scale bar 5 nm). e
Correlation average of the rota-
ry-shadowed crystal (scale bar
5 nm) (with permission to re-
produce from Elsevier Limited)
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factors might prolong the cellular life. However, also
VDAC alone may play a more important role not only as
adaptor for apoptotic factors but also as part of the
permeability transition pore complex. This complex can
potentially—after breakdown of the inner membrane
potential—also independently of apoptotic factors initiate
membrane permeability for certain mitochondrial factors.
Direct interactions between VDAC and potential drugs
have been demonstrated over the past few years. A direct
interaction between VDAC and the anti-depressant fluox-
etine has been shown but a biological function of such a
complex is still questionable (Nahon et al. 2006). More-
over, very recently HVDAC2 has been shown to be a
potential target of erastin, a small compound which turned
Fig. 3 Crystallization and crystallographic analysis of HVDAC1
crystals—from the crystal to the electron density and model. a Crystal
of the protein embedded in a loop kept in the mother liquor and frozen
in liquid nitrogen. b SDS-gel of this protein crystal dissolved in water
demonstrated a single protein band which was later identified as
human VDAC1 by MALDI-MS techniques and N-terminal sequenc-
ing. c Diffraction pattern of HVDAC1 taken at the beamline PXII of
the synchrotron light source SLS, Villigen, Switzerland. d Electron
density of the protein based on MAD-phases (from three SeMet
scatterers of the protein calculated at 6 Å resolution). The dimeric
structure of the protein, the diameter of approx. 3 nm and the
localization of the N-terminal helix within the barrel are visible
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out to be a potential inhibitor specific to cancer cells
(Yagoda et al. 2007). The disruption of the HVDAC1-
hexokinase complex has been demonstrated as a potential
way of treating tumors using the plant hormone methyl
jasmonate (Galluzzi et al. 2008).
Our current work is aiming to solve the structure of
HVDAC1 at the resolution given and to improve the crystals
quality to attain higher resolution, which is a prerequisite to
better understand not only the channel architecture but may
also allow to define substrate and target complexes in the
near future.
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